ENvue Medical, Inc.

As of June 30, 2026, ENvue Medical, Inc. carries a market capitalization of 50.64M, placing it among publicly traded companies globally. Its enterprise value stands at 50.87M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ENvue Medical, Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, ENvue Medical, Inc. has 8.19M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 8.34, and the price-to-book ratio stands at 1.65.

These figures are as of June 30, 2026. The EV/Sales ratio of 26.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 50.87M versus a market cap of 50.64M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ENvue Medical, Inc. maintains a current ratio of 0.66, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.26, indicating elevated leverage, while an interest coverage ratio of -212.56 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ENvue Medical, Inc. posted a negative return on equity (ROE) of -68.80, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -46.87, reflecting losses generated across the asset base. The company generates approximately 105,534.25 in revenue per employee across its workforce of 18.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.01 indicates how many times ENvue Medical, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ENvue Medical, Inc. recorded an income tax benefit of -353,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -21.42M and -21.06M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 15, 2026, ENvue Medical, Inc.'s stock has declined approximately 99.20% over the past 52 weeks. The 50-day moving average sits at 4.61, while the 200-day moving average is 18.77.

Over the twelve months ended June 30, 2026, ENvue Medical, Inc. generated 1.93M in revenue and converted that into -21.06M in net income, yielding earnings per share of -8.10. EBITDA reached -25.29M, while operating income came in at -15.09M.

As of June 30, 2026, ENvue Medical, Inc. holds 1.08M in cash and equivalents against 1.31M in total debt, resulting in a net debt position of -4,000.00. Total book value stands at 30.76M, with working capital of -2.49M providing operational flexibility.

ENvue Medical, Inc. produced -11.65M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -95,000.00 in capital expenditures, free cash flow totaled -11.74M - equivalent to -4.52 per share.

Over the twelve months ended June 30, 2026, ENvue Medical, Inc. posted a gross margin of -26.06, reflecting its pricing power and cost economics. The operating margin of -783.59 and net profit margin of -1,093.61 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of 14.04 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -73.11: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -17.42, meaning ENvue Medical, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

ENvue Medical, Inc.'s most recent stock split took place on September 1, 2026 with a 12:1 split ratio.

As of June 30, 2026, ENvue Medical, Inc. has an Altman Z-Score of -38.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.